{"id":"olmesartan-medoxomil-tablets-low-dose","brandName":"Olmesartan medoxomil tablets low dose","genericName":"Olmesartan medoxomil tablets low dose","companyId":"daiichi-sankyo-europe-gmbh-a-daiichi-sankyo-company","companyName":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","phase":"marketed","status":"active","modality":"Small molecule","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"Olmesartan medoxomil tablets (low dose) is an angiotensin II receptor blocker (ARB) marketed by Daiichi Sankyo Europe for hypertension management. The drug selectively blocks the AT1 angiotensin II receptor, preventing vasoconstriction and reducing blood pressure through a well-established mechanism. Approved across Europe and other markets, olmesartan is indicated for essential hypertension as monotherapy or in combination with other antihypertensive agents. Clinical evidence demonstrates efficacy in reducing systolic and diastolic blood pressure, with particular benefit in patients with metabolic syndrome and cardiovascular risk factors. The low-dose formulation provides flexible dosing for treatment initiation and titration, competing in the mature ARB market alongside losartan, valsartan, and irbesartan. Commercial significance is moderate within the broader antihypertensive class, with generic competition present in most markets post-patent expiry.","enrichmentLevel":3,"visitCount":0,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Olmesartan medoxomil is a prodrug that is hydrolyzed to olmesartan, an angiotensin II receptor blocker (ARB). It selectively antagonizes AT1 receptors on vascular smooth muscle and other tissues, blocking the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced peripheral vascular resistance, and decreased blood pressure.","oneSentence":"Olmesartan medoxomil blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure.","_ai_confidence":"high"},"administration":{},"safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Renal impairment"},{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Fatigue"}]},"trials":[],"indications":{"approved":[{"name":"Hypertension"}]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[{"nctId":"NCT05411887","phase":"","title":"Study to Evaluate the Effect of Improving Systolic BP and LDL-C Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-06-20","conditions":["Hyperlipidemias","Hypertension"],"enrollment":2845,"completionDate":"2025-12-31"},{"nctId":"NCT00891267","phase":"PHASE3","title":"Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2008-10","conditions":["Metabolic Syndrome","Hypertension"],"enrollment":60,"completionDate":"2011-05"}],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}